Fortress Biotech Reports Q3 2026 Revenue Growth Driven by Dermatology Portfolio and Emrosi Sales
Fortress Biotech (FBIO) reported third-quarter 2026 consolidated net revenue of $19.2 million, a 9% increase year-over-year. This growth was primarily fueled by its dermatology portfolio, specifically through Journey Medical, which saw an 11% rise in product sales to $18.9 million. The company's Emrosi product showed strong momentum with 40,000 prescriptions and a growing prescriber base of 5,000 unique writers. Despite the revenue growth, the company reported a consolidated net loss of $7.9 million ($0.23 per share), compared to a profit in the prior year's quarter. This shift was influenced by increased R&D spending and one-time settlement costs. However, Fortress Biotech maintains a strong liquidity position with $152.2 million in cash and cash equivalents, bolstered significantly by a $158.9 million gain from the sale of a priority review voucher during the first nine months of the year.
Topics: debt repayment dermatology sales net loss prescription volume revenue growth